Findings

What do systematic reviews say?

14 questions · 14 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 9 · 64.3%GRADE not reported 0 · 0%Very low 2 · 14.3%Low 3 · 21.4%Moderate 0 · 0%High 0 · 0%

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

Treatment time · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

Quality of life · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

Serum deposition Cmax · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

Adverse events · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

FEV1 · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

Time to next exacerbation · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

Participant satisfaction or preference · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

Treatment time (minutes) · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 85 participants
Low

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

Quality of life CFQ‐R scores (treatment burden domain and respiratory domain) · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 85 participants
Very low

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

Serum deposition Cmax · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 85 participants
Very low

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

FEV1 % predicted · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 85 participants
Low

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

Time to next exacerbation · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

Participant satisfaction or preference · adults and children with cystic fibrosis

Summary of findings ‐ nebulisers for delivering dornase alfa:… may leads to lower participant satisfaction or preference: compared with VMT (low certainty).

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
RR 0.48 [0.31, 0.76]
1 study · 68 participants
Low